Joseph Reisman, Partner, Knobbe Martens Olson & Bear LLP to Speak at TKG’s Event
New York, NY, December 13, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Joseph Reisman, Partner, Knobbe Martens Olson & Bear LLP will speak at the Knowledge Group’s webcast entitled: “The Hatch-Waxman Act: Recent Amendments and Developments Live Webcast.” This event is scheduled for December 14, 2017 at 12:00 PM - 1:30 PM ET.
For further details, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About Joseph Reisman
Joseph Reisman is a partner in Knobbe Martens’ San Diego office. He obtained a B.S. and a Ph.D. in Chemistry at, respectively, Yale University and the University of California (San Diego), and a J.D. at the University of California (Berkeley). He served as a Law Clerk to Alan D. Lourie of the Court of Appeals for the Federal Circuit. His practice involves patent prosecution and strategic counseling for pharmaceutical clients, developing and enforcing patent portfolios. He has also served as counsel for numerous generic pharmaceutical manufacturers, and has been instrumental in developing and implementing strategies for achieving early market entry of numerous generic products including atorvastatin (Lipitor) an valganciclovir (Valcyte). He serves as an adjunct professor at the University of San Diego and is a member of the Board of Directors of the Federal Circuit Bar Association.
About Knobbe Martens Olson & Bear LLP
Knobbe Martens is an agent of innovation, with offices across California, as well as in New York, Seattle, and Washington, D.C. We provide clients worldwide with forward-focused Intellectual Property and Technology law service and representation. Knobbe Martens is one of the world’s largest Intellectual Property law firms, with more than 300 attorneys and scientists representing the complete spectrum of technologies and Intellectual Property practice areas. We combine unmatched technical and litigation expertise to deliver superior results in both transactional and contested matters, for both cutting edge start-ups and established Fortune 500 companies, in fields ranging from physics to pharmaceuticals and entertainment to engineering. For more information, please visit knobbe.com.
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications - approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This live webcast will discuss the following key topics:
The Hatch-Waxman Act: Overview and Legal Framework
Latest Developments
The Abbreviated New Drug Application (ANDA) Process
Latest Developments in ANDA Litigation
Recent FDA Applications
The Hatch-Waxman Act in 2018 – An Outlook
About The Knowledge Group /The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About Joseph Reisman
Joseph Reisman is a partner in Knobbe Martens’ San Diego office. He obtained a B.S. and a Ph.D. in Chemistry at, respectively, Yale University and the University of California (San Diego), and a J.D. at the University of California (Berkeley). He served as a Law Clerk to Alan D. Lourie of the Court of Appeals for the Federal Circuit. His practice involves patent prosecution and strategic counseling for pharmaceutical clients, developing and enforcing patent portfolios. He has also served as counsel for numerous generic pharmaceutical manufacturers, and has been instrumental in developing and implementing strategies for achieving early market entry of numerous generic products including atorvastatin (Lipitor) an valganciclovir (Valcyte). He serves as an adjunct professor at the University of San Diego and is a member of the Board of Directors of the Federal Circuit Bar Association.
About Knobbe Martens Olson & Bear LLP
Knobbe Martens is an agent of innovation, with offices across California, as well as in New York, Seattle, and Washington, D.C. We provide clients worldwide with forward-focused Intellectual Property and Technology law service and representation. Knobbe Martens is one of the world’s largest Intellectual Property law firms, with more than 300 attorneys and scientists representing the complete spectrum of technologies and Intellectual Property practice areas. We combine unmatched technical and litigation expertise to deliver superior results in both transactional and contested matters, for both cutting edge start-ups and established Fortune 500 companies, in fields ranging from physics to pharmaceuticals and entertainment to engineering. For more information, please visit knobbe.com.
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications - approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This live webcast will discuss the following key topics:
The Hatch-Waxman Act: Overview and Legal Framework
Latest Developments
The Abbreviated New Drug Application (ANDA) Process
Latest Developments in ANDA Litigation
Recent FDA Applications
The Hatch-Waxman Act in 2018 – An Outlook
About The Knowledge Group /The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories